Author: Tyler Holt

Kineticos Announces New Life Sciences Disruptor Fund That Will Launch and Invest in Early Stage Biotechs

February 6, 2020 – Raleigh, NC – Kineticos announced today the Kineticos Disruptor Fund, a new life sciences investment fund. The fund will invest in disruptive modalities including cell therapy approaches such as CAR Ts, TCRs, TILs, gene therapy, gene editing, RNAi, immuno-oncology, and related precision medicine technologies.

The Kineticos Disruptor Fund will focus on large, unmet medical needs in oncology, neurosciences and rare diseases. In oncology, new approaches to solid tumors and “off the shelf” allogeneic cell therapies are immediate priorities. Kineticos will support entrepreneur-scientists and the biotech community through Series A funding.

In addition to supporting existing biotechs, the Kineticos Disruptor Fund will work with technology partners, including leading universities and other research centers. In this venture creation model, Kineticos will in-license technologies and build teams from its extensive community of advisors to advance new platforms.

Kineticos’ Founder and CEO, Shailesh Maingi states: “Our core mission is to advance life science research by supporting biotech companies in their pursuit of new treatments for patients. Yet, today with the most difficult to treat diseases, such as cancer, advancement is measured in months of increased life expectancy. With the advent and success of new disruptive technologies in life sciences, we believe how medicine is practiced today is fundamentally changing. For the first time, rational scientists, physicians, and entrepreneurs talk about a cure for cancer.”

He continued, “With the launch of the Kineticos Disruptor Fund, we are able to support the biotech community from concept to commercialization. I am very excited to work with my investment partners Mark Bamforth (Founder, Arranta Bio and previous Founder, Brammer Bio), Derek Hennecke (Founder, Xcelience) and Abe Maingi (VP, Kineticos) and I know of no better way to advance science than through capitalism.”

Paul Garofolo, Founder and CEO of Locus Biosciences, commented: “From the early days when we incubated with Kineticos, their team has been an important ally for Locus to lean on as we advanced our crPhage platform. At each stage of our company’s growth they have helped advise our team on how to best position our assets and overall company strategy for that stage of the company’s evolution. Their business and scientific insights have proven invaluable.”

Dr. Amit Vohra, Founder and CEO of Promaxo: “Since the early days of Promaxo, Kineticos has been an important ally. They have consistently focused on our needs and helped us advance our innovative modular MRI platform. Kineticos business and scientific acumen has resonated with our team.”

About Kineticos:

Kineticos is an award-winning organization supporting Biopharmaceutical and Precision Medicine firms. Launched in 2007, Kineticos initially concentrated on strategy, licensing, and market access support for Precision Medicine firms. In 2012, Kineticos launched its Biopharmaceutical practice. In 2016, Kineticos launched its internal think tank, The Kineticos Research Institute, which includes the Biotech CEO Confidence Index, The Disruptor26 podcast series, white papers, and other relevant content. In 2019, Kineticos was selected as Life Science Consultant of the Year.

In 2020, with the launch of the Kineticos Disruptor Fund, Kineticos recognized the need for a new model to support life science start-ups integrating intelligent funding, biotech expertise, and thoughtful execution. Kineticos has a deep and talented community of advisors to support biotech formation and funding. Ongoing relationships with larger pharmaceutical and biotech companies provide our portfolio companies with numerous opportunities for research collaborations and non-dilutive funding.

Additional information about Kineticos is available at www.kineticos.com. Inquiries can be sent to Philip Gialenios at philip.gialenios@kineticos.com.

Kineticos Welcomes New Senior Team Member – Dan McCormick

October 23, 2019 – Raleigh, NC – Kineticos Life Sciences announces the further expansion of their senior leadership team with the addition of Dan McCormick, Senior Vice President, Biopharma Practice.

Mr. McCormick brings to Kineticos a track record of over 20 years of success in biopharma, devices, and diagnostics, following 4 years of service as an officer in the Marine Corps. His broad perspective is a culmination of experience that spans numerous sales, marketing, value & access, strategy & operations, and medical affairs roles. He has worked across multiple specialties to engage providers, payers, and patient advocacy groups.

Prior to joining Kineticos, Mr. McCormick worked for Amgen, Baxter, and Dianon Pathology.  Along with a manufacturer’s perspective, Dan intimately understands the service side from both a client and contractor perspective, having held recent executive leadership accountabilities with a commercial contract organization. Much of his career has been spent building and operationalizing plans focused on profitable growth in US and Global markets. Applying his Commercial learnings to increase overall Medical Affairs effectiveness, Mr. McCormick has also developed innovative solutions for MSL organizations. Dan has earned a reputation for challenging the status quo to refocus resources for greatest impact using analytics, efficient channels, and technologies. Frequently solicited for his strategic expertise, his recent accolades include: PHARMAfield UK Magazine’s “Movers & Shakers” (Oct 2018) and PM360 Magazine’s “2018 Innovators” Award (Dec 2018).

Shailesh Maingi, CEO and Founder of Kineticos, stated, “We’re excited to have Dan join the firm. Dan brings with him a wealth of experience and a track record of success that will broaden and deepen Kineticos’ ability to deliver innovative solutions for our BioPharma clients. This addition to Kineticos Leadership Team is another step toward supporting our overall strategy and position the firm for our next phase of ongoing growth.”

When asked about his new role, Mr. McCormick stated, “Kineticos is at an inflection point. Along with expanding the senior leadership team, Shailesh’s recent integration of the Disruptor Fund to our offerings illustrates a strong commitment to fully support biopharma’s focus on patient outcomes. I’m excited to be a part of a firm with capabilities that now offer a full continuum of value, from start-up financing to Phase III support and beyond.“

Recently recognized with a 2019 Life Sciences Consultant of The Year award by the Triangle Business Journal, Kineticos Life Sciences continues to strengthen its position as an industry leader.

 

About Kineticos

Kineticos is a life science strategy consulting firm serving the Biopharmaceutical and Precision Medicine markets.  Our mission is simple: to improve patient outcomes. Every day, we see how therapeutic and precision medicine biotechs are changing the standard of care in medicine. With over 6,000 firms globally, biotechs are the catalysts of innovation in life sciences today. Yet, emerging companies often have limited resources to focus on strategy.

Addressing these challenges is at the core of our capabilities. Join us in our mission to improve patient outcomes by advancing the boundaries of scientific research.


Media Contact

Nathan Finger, Director of Marketing

nathan.finger@kineticos.com

Meet Kevin Hampton, SVP of Kineticos’ Early Stage Biopharma Practice

With Kineticos’ team expansion, Kevin Hampton has transitioned to leading the Biopharmaceutical Early Stage Practice. Kevin brings experience within Kineticos’ Finance, Marketing, Operations, and Commercial teams to grow the Biopharmaceutical Practice.

 

To learn more about Kevin Hampton and his plans for the Biopharmaceutical Practice click below.

 

Meet Kevin Hampton, SVP of Kineticos’ Early Stage Biopharma Practice

 

To connect with Kevin Hampton on LinkedIn click here

Kineticos Wins Triangle Business Journal’s 2019 Life Sciences Consultant of the Year

June 6, 2019 – Raleigh, NC – Kineticos, a management consulting firm serving the life sciences community, has been selected as Triangle Business Journal’s 2019 Life Sciences Consultant of the Year. Kineticos’ Founder and CEO, Shailesh Maingi received the award on behalf of the organization at Triangle Business Journal’s Annual Life Sciences Awards Ceremony at the Umstead Hotel and Spa.

Shailesh, who founded the company in 2007, had this to say: “This award is a testament of the great team we have at Kineticos and our team’s ability to address our biotechnology sponsor’s most complex problems. While we are incredibly grateful, we understand our work is not done. Our mission is to improve patient outcomes through our consulting team, our new biotechnology accelerator model, proprietary data analytics and internal think tank, Kineticos Research Institute.”

Kineticos Chief Commercial Officer, Kevin Hampton, who grew up in Raleigh, commented on this as well: “We have clients all over the world but to be recognized by a local publisher such as the TBJ means the world to us. This award is a result of the entire team’s hard work along with our passion to help our clients in their quest for developing life changing therapies for patients in need.”

Paul Garofolo, Founder and CEO of Locus Biosciences, congratulated the firm: “Kineticos was instrumental in helping Locus Biosciences launch our startup operations inside the RTP area. Their senior consulting teams worked alongside our founders to establish the initial sets of Target Product Profiles that underpinned our CRISPR-Cas3 platform technology play. We could not speak more highly of the Kineticos team and support provided to Locus in the early days of our endeavor.”

 

About Kineticos:

At Kineticos, our mission is simple: to improve patient outcomes. Every day, we see how therapeutic and precision medicine biotechs are changing the standard of care in medicine. With over 6,000 firms globally, biotechs are the catalysts of innovation in life sciences today. Yet, emerging and specialty biotechs often have limited resources to focus on strategy.

What’s the optimal R&D portfolio strategy in a highly regulated, complex and expensive clinical research environment? What’s an effective licensing strategy to identify potential partners and negotiate transactions? With reimbursement and pricing challenging, what’s the plan to ensure market access?

Addressing these challenges is at the core of our capabilities. Join us in our mission to improve patient outcomes by advancing the boundaries of scientific research.


Media Contact

Nathan Finger, Director of Marketing

nathan.finger@kineticos.com